Medios AG
ILM1 | F
Overview
Corporate Details
- ISIN(s):
- DE000A1MMCC8 (+1 more)
- LEI:
- 391200Z7Z09IHDBT2L23
- Country:
- Germany
- Address:
- Heidestraße 9, 10557 Berlin
- Website:
- https://medios.ag/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Medios AG is a leading European specialty pharmaceutical company focused on advancing individualized medicine. The company's core business involves the compounding of patient-specific therapies and the supply of specialty pharma solutions. It serves a diverse client base, including pharmacies, medical specialists, hospitals, and pharmaceutical companies, ensuring reliable access to innovative treatments for complex and chronic conditions. With a strong focus on therapeutic areas such as oncology, neurology, and autoimmune diseases, Medios pioneers the development and distribution of advanced therapies and biotechnological precision medicine. By integrating pharmaceutical supply with specialized compounding services, the company plays a crucial role in making personalized treatments accessible to patients.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Medios AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-04 15:00 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 12.3 KB | |
| 2025-08-28 10:15 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 13.5 KB | |
| 2025-08-27 10:37 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 13.2 KB | |
| 2025-08-13 07:37 |
Earnings Release
Medios accelerates growth in the first half of 2025 and significantly increases…
|
English | 20.0 KB | |
| 2025-08-13 00:00 |
Interim Report
Half-yearly financial report 2025
|
English | 500.4 KB | |
| 2025-07-18 11:41 |
Major Shareholding Notification
|
English | 5.4 KB | |
| 2025-07-11 09:55 |
Transaction in Own Shares
Medios successfully completes public share buyback offer
|
English | 11.0 KB | |
| 2025-06-18 19:16 |
Transaction in Own Shares
Medios adopts public share buyback offer for up to 1 million shares at a price …
|
English | 11.8 KB | |
| 2025-05-27 16:06 |
Post-Annual General Meeting Information
Medios AG Annual General Meeting 2025: Shareholders approve all proposed resolu…
|
English | 10.1 KB | |
| 2025-05-14 07:50 |
Earnings Release
Medios starts 2025 financial year successfully with significant increase in ear…
|
English | 20.7 KB | |
| 2025-05-13 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2025
|
English | 10.1 MB | |
| 2025-05-12 18:58 |
Board/Management Information
Medios repositions itself for the next phase of its corporate development
|
English | 12.7 KB | |
| 2025-04-14 15:06 |
Pre-Annual General Meeting Information
Medios AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.05.2025 in…
|
German | 256.2 KB | |
| 2025-03-25 07:50 |
Earnings Release
Medios expects further growth in revenue and earnings after record year 2024
|
English | 20.3 KB | |
| 2025-03-25 00:00 |
Annual Report
Annual financial report 2024
|
English | 4.1 MB |
Automate Your Workflow. Get a real-time feed of all Medios AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Medios AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-19 | van Rietschoten, Constantijn | Board | Buy | None | 162,805.82 EUR |
| 2023-06-28 | Prußeit, Christoph | Board | Buy | None | 39,100.00 EUR |
| 2021-12-09 | Miehler, Mi-Young | Board | Other | None | 3,550,000.00 EUR |
| 2021-12-09 | Prußeit, Christoph | Board | Other | None | 1,775,000.00 EUR |
| 2021-12-09 | Miehler, Mi-Young | Board | Other | None | 700,000.00 EUR |
| 2021-12-09 | Prußeit, Christoph | Board | Other | None | 350,000.00 EUR |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
